Theres no evidence that meal timing affects its absorption or efficacy
Semaglutide exposure was similar for the groups with moderate renal impairment and normal renal function
GLP-1s are changing obesity care but nutrition may be the silent side effect. As Jorge Urbina and colleagues highlight in a 2026 Clinical Obesity narrative review, GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) can predispose some patients to micronutrient and nutritional deficienciesvia appetite suppression, delayed gastric emptying, and altered intake/absorption
Furthermore, ongoing studies are exploring potential new applications for this medication, which could be relevant for those considering long-term treatment options
Whey concentrate c kh nng hp thu chm hn whey isolate v hydrolyzed
"Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol